Neuroendocrine tumor liver metastasis is the most common distant metastatic site for neuroendocrine tumors (NETs). Primary tumors are usually pancreatic NET, small bowel carcinoid, or lung carcinoid. Most common cause of hypervascular metastasis group. Shows intense, homogeneous enhancement in arterial phase — fundamentally different enhancement pattern from hypovascular metastases (colorectal, breast). Octreotide (somatostatin analogue) scintigraphy and Ga-68 DOTATATE PET-CT offer high sensitivity and specificity for diagnosis and staging.
Age Range
30-70
Peak Age
55
Gender
Equal
Prevalence
Uncommon
Neuroendocrine tumors originate from enterochromaffin cells and express somatostatin receptors (SSTR). Liver metastases form via portal venous drainage (GI tract NET) or hematogenous route (lung NET). NET metastases show intense arterial neovascularization — similar mechanism to HCC but based on different biology. NET cells intensely secrete VEGF and other angiogenic factors → new capillary network forms → intense arterial phase enhancement. Since somatostatin receptor expression is preserved, specific uptake is shown on octreotide scintigraphy and DOTATATE PET-CT. NET metastases usually grow slowly (low grade) and may remain stable for years, but high-grade (G3) NETs show aggressive course.
Multiple liver lesions with intense homogeneous enhancement in arterial phase + specific uptake on Ga-68 DOTATATE PET-CT is diagnostic for neuroendocrine metastasis. This combination distinguishes from HCC (cirrhosis + washout + capsule), other tumors causing hypervascular metastasis (RCC, thyroid, melanoma — no DOTATATE uptake), and hemangioma (peripheral nodular enhancement, no DOTATATE uptake).
Markedly intense and homogeneous enhancement compared to surrounding liver parenchyma in arterial phase. The most diagnostic finding of the hypervascular metastasis group. Even small lesions (<1 cm) appear bright in arterial phase. Hypovascular metastases like colorectal show weak enhancement in arterial phase — not confused with NET metastasis.
Report Sentence
Multiple lesions demonstrating intense homogeneous enhancement in arterial phase are observed in the liver, consistent with hypervascular metastasis.
Lesions may be isointense or mildly hypointense in portal venous phase. Different from the prominent nonperipheral washout in HCC — enhancement persists longer in NET metastases. Some lesions may still remain mildly hyperdense in portal venous phase.
Report Sentence
The lesions appear isointense/mildly hypointense in portal venous phase, with partial persistence of enhancement.
Moderately hyperintense signal on T2-weighted images. Not as bright as hemangioma, shows slightly more homogeneous hyperintensity than HCC. Central necrosis may be T2 hyperintense in large lesions.
Report Sentence
The lesions demonstrate moderate homogeneous hyperintense signal on T2-weighted sequences.
Hyperintensity on DWI and low values on ADC. High cellularity causes diffusion restriction. DWI is particularly useful for detection of small lesions.
Report Sentence
Diffusion restriction is observed in the lesions on DWI sequences, consistent with cellular metastasis.
Specific uptake in lesions on Ga-68 DOTATATE PET-CT. The most sensitive and specific imaging method for NET metastases expressing somatostatin receptor (SSTR2). Superior to FDG-PET (low-grade NETs show low FDG uptake). Octreotide scintigraphy (In-111 OctreoScan) is an alternative but sensitivity is lower than DOTATATE PET.
Report Sentence
Intense somatostatin receptor uptake is observed in liver lesions on Ga-68 DOTATATE PET-CT, consistent with neuroendocrine tumor metastasis.
Criteria
Ki-67 index <20%, low mitotic rate. Slow growth, may remain stable for years.
Distinct Features
Intense homogeneous arterial enhancement. High DOTATATE uptake. Low FDG uptake. Good response to somatostatin analogue therapy (PRRT — Lu-177 DOTATATE eligible).
Criteria
Ki-67 index >20%, high mitotic rate. Rapid growth, aggressive course.
Distinct Features
Heterogeneous enhancement (necrosis common). Low or absent DOTATATE uptake (receptor loss). High FDG uptake. Requires chemotherapy (cisplatin-based). Poor prognosis.
Criteria
Systemic release of serotonin, histamine, or other vasoactive substances. Carcinoid syndrome develops after liver metastasis (loss of hepatic first-pass).
Distinct Features
Flushing, diarrhea, wheezing, carcinoid heart disease. Elevated urinary 5-HIAA level. Symptom control with somatostatin analogue. Debulking surgery may reduce symptoms.
Distinguishing Feature
HCC develops in cirrhosis, single or few lesions, shows APHE + washout + capsule. NET metastasis in non-cirrhotic liver, multiple, intense homogeneous enhancement, washout not prominent. AFP elevated in HCC, chromogranin A elevated in NET.
Distinguishing Feature
Hemangioma shows peripheral nodular enhancement + centripetal filling — homogeneous enhancement in NET metastasis. Hemangioma very bright on T2 ('light bulb sign'), NET metastasis moderately hyperintense. Hemangioma does not take up DOTATATE.
Distinguishing Feature
RCC metastasis can also be hypervascular but does not take up DOTATATE. Renal primary tumor history is distinguishing. RCC metastases are more heterogeneous (necrosis and hemorrhage common), NET metastases more homogeneous.
Distinguishing Feature
Melanoma metastasis may be T1 hyperintense (melanin), T2 hypointense (paramagnetic melanin). These signal characteristics are not seen in NET metastasis. Melanoma history and skin examination are distinguishing. Melanoma does not take up DOTATATE.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthTreatment of NET liver metastases requires a multidisciplinary approach. Low grade (G1-G2): somatostatin analogue (octreotide LAR, lanreotide) is first-line therapy — slows tumor growth and controls carcinoid syndrome symptoms. PRRT (peptide receptor radionuclide therapy — Lu-177 DOTATATE) is effective in SSTR-positive tumors. Hepatic arterial embolization/chemoembolization (TAE/TACE) is effective due to hypervascular nature. Surgical resection or debulking is applied in selected cases. Everolimus and sunitinib (targeted therapy) are used in progression. High grade (G3): cisplatin-based chemotherapy. Chromogranin A and 5-HIAA are follow-up markers.
NET patients with liver metastases may show prolonged survival. Treatment options include surgical resection, hepatic artery embolization (TAE/TACE), peptide receptor radionuclide therapy (PRRT), and somatostatin analogs. Ga-68 DOTATATE PET/CT is the gold standard for staging.